

Andrew P Cope

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7405691/publications.pdf>

Version: 2024-02-01

42
papers

2,838
citations

279798

23
h-index

254184

43
g-index

48
all docs

48
docs citations

48
times ranked

4993
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 638-641.	0.9	354
2	Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells. <i>Nature Immunology</i> , 2010, 11, 862-871.	14.5	249
3	The Th1 life cycle: molecular control of IFN- γ to IL-10 switching. <i>Trends in Immunology</i> , 2011, 32, 278-286.	6.8	203
4	Why is <i>PTPN22</i> a good candidate susceptibility gene for autoimmune disease?. <i>FEBS Letters</i> , 2011, 585, 3689-3698.	2.8	194
5	Innate-like T cells straddle innate and adaptive immunity by altering antigen-receptor responsiveness. <i>Nature Immunology</i> , 2014, 15, 80-87.	14.5	180
6	Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events. <i>Nature Immunology</i> , 2016, 17, 204-213.	14.5	148
7	T cells in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2008, 10, S1.	3.5	142
8	Bayesian cluster identification in single-molecule localization microscopy data. <i>Nature Methods</i> , 2015, 12, 1072-1076.	19.0	124
9	Prolonged Exposure of T Cells to TNF Down-Regulates TCR α and Expression of the TCR/CD3 Complex at the Cell Surface. <i>Journal of Immunology</i> , 2001, 166, 5495-5507.	0.8	117
10	Studies of T-cell activation in chronic inflammation. <i>Arthritis Research</i> , 2002, 4, S197.	2.0	109
11	The cholesterol biosynthesis pathway regulates IL-10 expression in human Th1 cells. <i>Nature Communications</i> , 2019, 10, 498.	12.8	98
12	Lack of the Phosphatase PTPN22 Increases Adhesion of Murine Regulatory T Cells to Improve Their Immunosuppressive Function. <i>Science Signaling</i> , 2012, 5, ra87.	3.6	97
13	T cell responses to a human cartilage autoantigen in the context of rheumatoid arthritis-associated and nonassociated HLA-DR4 alleles. <i>Arthritis and Rheumatism</i> , 1999, 42, 1497-1507.	6.7	95
14	TNF- α blockade induces IL-10 expression in human CD4+ T cells. <i>Nature Communications</i> , 2014, 5, 3199.	12.8	95
15	Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol. <i>Trials</i> , 2019, 20, 429.	1.6	77
16	A Bayesian cluster analysis method for single-molecule localization microscopy data. <i>Nature Protocols</i> , 2016, 11, 2499-2514.	12.0	55
17	Multiple cross-reactive self-ligands for <i>Borrelia burgdorferi</i> -specific HLA-DR4-restricted T cells. <i>European Journal of Immunology</i> , 2000, 30, 448-457.	2.9	53
18	Cholesterol metabolism drives regulatory B cell IL-10 through provision of geranylgeranyl pyrophosphate. <i>Nature Communications</i> , 2020, 11, 3412.	12.8	47

#	ARTICLE	IF	CITATIONS
19	Anti- TNF± Therapy of Rheumatoid Arthritis: What Can We Learn about Chronic Disease?. Novartis Foundation Symposium, 2008, , 53-73.	1.1	38
20	Superresolution imaging of the cytoplasmic phosphatase PTPN22 links integrin-mediated T cell adhesion with autoimmunity. Science Signaling, 2016, 9, ra99.	3.6	37
21	3D Bayesian cluster analysis of super-resolution data reveals LAT recruitment to the T cell synapse. Scientific Reports, 2017, 7, 4077.	3.3	36
22	Emerging approaches for the therapy of autoimmune and chronic inflammatory disease. Current Opinion in Immunology, 2004, 16, 780-786.	5.5	34
23	Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritisâ€”a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology, 2017, 56, 2004-2014.	1.9	27
24	Topographic prominence as a method for cluster identification in singleâ€”molecule localisation data. Journal of Biophotonics, 2015, 8, 925-934.	2.3	25
25	T cell receptor Â reconstitution fails to restore responses of T cells rendered hyporesponsive by tumor necrosis factor Â. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1696-1701.	7.1	24
26	Inhibitor of Kappa B Epsilon (ÎºBÎµ) Is a Non-Redundant Regulator of c-Rel-Dependent Gene Expression in Murine T and B Cells. PLoS ONE, 2011, 6, e24504.	2.5	23
27	Protein tyrosine phosphatase PTPN22 regulates ILâ€”1Î² dependent Th17 responses by modulating dectinâ€”1 signaling in mice. European Journal of Immunology, 2018, 48, 306-315.	2.9	17
28	The protein tyrosine phosphatase PTPN22 negatively regulates presentation of immune complex derived antigens. Scientific Reports, 2018, 8, 12692.	3.3	17
29	Multi-color Molecular Visualization of Signaling Proteins Reveals How C-Terminal Src Kinase Nanoclusters Regulate T Cell Receptor Activation. Cell Reports, 2020, 33, 108523.	6.4	15
30	Emerging therapies for pre-RA. Best Practice and Research in Clinical Rheumatology, 2017, 31, 99-111.	3.3	14
31	Expectations of new treatment in rheumatoid arthritis: developing a patientâ€”generated questionnaire. Health Expectations, 2015, 18, 995-1008.	2.6	12
32	Differential nanoscale organisation of LFA-1 modulates T-cell migration. Journal of Cell Science, 2020, 133, .	2.0	12
33	A systematic review of CXCL13 as a biomarker of disease and treatment response in rheumatoid arthritis. BMC Rheumatology, 2020, 4, 70.	1.6	12
34	Protein tyrosine phosphatase PTPN22 is dispensable for dendritic cell antigen processing and promotion of T-cell activation by dendritic cells. PLoS ONE, 2017, 12, e0186625.	2.5	11
35	The impact of COVID-19 on clinical care, self-management and mental health of patients with inflammatory arthritis. Rheumatology Advances in Practice, 2022, 6, rkab095.	0.7	10
36	Altered signalling thresholds in T lymphocytes cause autoimmune arthritis. Arthritis Research, 2004, 6, 112.	2.0	9

#	ARTICLE	IF	CITATIONS
37	Considerations for Optimal Trial Design for Rheumatoid Arthritis Prevention Studies. <i>Clinical Therapeutics</i> , 2019, 41, 1299-1311.	2.5	8
38	Harmful Waste Products as Novel Immune Modulators for Treating Inflammatory Arthritis?. <i>PLoS Medicine</i> , 2006, 3, e385.	8.4	4
39	Adding New Perspectives to the Kaleidoscope of Remission Criteria in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2013, 40, 353-355.	2.0	2
40	Psychometric properties of a new treatment expectation scale in rheumatoid arthritis: an application of item response theory. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 239.	1.9	1
41	Multiple cross-reactive self-ligands for <i>Borrelia burgdorferi</i> -specific HLA-DR4-restricted T cells. <i>European Journal of Immunology</i> , 2000, 30, 448-457.	2.9	1
42	Aging, autoimmunity and arthritis: an introduction. <i>Arthritis Research</i> , 2003, 5, 223.	2.0	0